+128.7%
VXUS vs MRNA
+537.9%
-409.1%
-34.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | -3.6% | +3.2% | -0.3% |
| 7D | +1.6% | -9.0% | +10.6% | +1.9% |
| 30D | +1.0% | +137.2% | -136.2% | -4.4% |
| 3M | +5.7% | +194.8% | -189.2% | -1.4% |
| 6M | +13.6% | +167.2% | -153.6% | +6.4% |
| YTD | +17.4% | +375.9% | -358.5% | +6.6% |
| 1Y | +25.1% | +465.2% | -440.1% | +12.3% |
| 3Y | +75.8% | +30.4% | +45.5% | +65.6% |
| 5Y | +55.4% | -66.8% | +122.2% | +48.6% |
| All | +128.7% | +537.9% | -409.1% | +108.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling